"gMG race hots up as AstraZeneca’s star candidate meets Phase III targets" was originally created and published by Clinical ...

Alexion, the rare disease unit acquired by AstraZeneca nearly five years ago, has announced high-level positive results from ...

Results from the Phase III PREVAIL trial (NCT05556096) of gefurulimab demonstrated a statistically significant and clinically ...

UK pharma major AstraZeneca is preparing to advance gefurulimab as a potential new treatment for generalized myasthenia ...